Key result
Discontinuing IFN-beta-1a in secondary progressive MS is linked to increased neurological disability and brain lesions.
Why the study?
Does discontinuation of IFN-beta-1a increase neurological disability and brain lesions on MRI in patients with secondary progressive multiple sclerosis?
Observational (n=21)
Does discontinuation of IFN-beta-1a increase neurological disability and brain lesions on MRI in patients with secondary progressive multiple sclerosis?
Discontinuation of IFN-beta-1a in secondary progressive MS is associated with significant worsening of neurological disability and increased brain lesions on MRI.
No takes yet. Share an insight, caveat, or question.
May support continued IFN-beta-1a in SPMS; leaves open need for RCTs to confirm disability risk.
Wu et al. (2005) conducted an observational in Secondary progressive multiple sclerosis (SPMS) (n=21). Discontinuation of interferon (IFN)-beta-1a vs. Treatment period (on IFN-beta-1a) was evaluated on Neurological disability (EDSS) and brain lesions on MRI. Discontinuation of IFN-beta-1a in secondary progressive multiple sclerosis was associated with a significant increase in neurological disability and brain lesions on MRI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: